143 related articles for article (PubMed ID: 36786360)
21. Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy.
Dick A; Rosenbloom JI; Karavani G; Gutman-Ido E; Lessans N; Chill HH
Am J Obstet Gynecol MFM; 2022 Jul; 4(4):100637. PubMed ID: 35398583
[TBL] [Abstract][Full Text] [Related]
22. COVID-19 pandemic and autoimmune bullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation.
Kasperkiewicz M; Yale M; Strong R; Zillikens D; Woodley DT; Recke A
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e418-e421. PubMed ID: 33724560
[No Abstract] [Full Text] [Related]
23. Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine.
Koutlas IG; Camara R; Argyris PP; Davis MDP; Miller DD
Oral Dis; 2022 Nov; 28 Suppl 2():2612-2613. PubMed ID: 34825752
[No Abstract] [Full Text] [Related]
24. Safety of the COVID-19 vaccine booster in patients with immunobullous diseases: A cross-sectional study of the International Pemphigus and Pemphigoid Foundation.
Kasperkiewicz M; Strong R; Yale M; Dunn P; Woodley DT
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):e9-e10. PubMed ID: 35964297
[No Abstract] [Full Text] [Related]
25. Nicolau Syndrome After Glatiramer Acetate Injection in Close Proximity to Administration of SARS-CoV-2 mRNA Vaccine.
Sy MY; Fromm E; Doan L; Rojek N; Brandt AU
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34759023
[No Abstract] [Full Text] [Related]
26. Vaccine inequality may undermine the booster programme.
Haque Z
BMJ; 2021 Dec; 375():n3118. PubMed ID: 34921004
[No Abstract] [Full Text] [Related]
27. Development of immediate and chronic spontaneous urticaria following mRNA COVID-19 vaccination: Tolerability of revaccination and immunological study.
Teo RXW; Leung BPL; Thong BY; Tan JWL; Chan GYL; Lim XR
Ann Acad Med Singap; 2024 Jan; 53(1):57-59. PubMed ID: 38920217
[No Abstract] [Full Text] [Related]
28. Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease.
Connolly CM; Frey S; Chiang TP; Teles M; Alejo JL; Albayda J; Shah AA; Werbel WA; Segev DL; Christopher-Stine L; Paik JJ
Rheumatology (Oxford); 2022 Oct; 61(10):e302-e304. PubMed ID: 35583259
[No Abstract] [Full Text] [Related]
29. Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine.
Agharbi FZ; Eljazouly M; Basri G; Faik M; Benkirane A; Albouzidi A; Chiheb S
Ann Dermatol Venereol; 2022 Mar; 149(1):56-57. PubMed ID: 34686374
[No Abstract] [Full Text] [Related]
30. [Not Available].
Jacquérioz F
Rev Med Suisse; 2022 Feb; 18(769):298. PubMed ID: 35188356
[No Abstract] [Full Text] [Related]
31. Vaccination after prior COVID-19 infection: Implications for dose sparing and booster shots.
Kent SJ; Juno JA
EBioMedicine; 2021 Oct; 72():103586. PubMed ID: 34536815
[No Abstract] [Full Text] [Related]
32. Oral mucous membrane pemphigoid after SARS-CoV-2 vaccination.
Calabria E; Antonelli A; Lavecchia A; Giudice A
Oral Dis; 2024 Mar; 30(2):782-783. PubMed ID: 36516333
[No Abstract] [Full Text] [Related]
33. Bullous pemphigoid and COVID-19 vaccination: Management and treatment reply to 'Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: A report and brief literature review' by Pauluzzi et al.
Martora F; Ruggiero A; Battista T; Fabbrocini G; Megna M
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):e35-e36. PubMed ID: 35974447
[No Abstract] [Full Text] [Related]
34. Bullous pemphigoid and COVID-19 vaccine.
Pérez-López I; Moyano-Bueno D; Ruiz-Villaverde R
Med Clin (Barc); 2021 Nov; 157(10):e333-e334. PubMed ID: 34119340
[No Abstract] [Full Text] [Related]
35. Strategies and safety considerations of booster vaccination in COVID-19.
Meng H; Mao J; Ye Q
Bosn J Basic Med Sci; 2022 Jun; 22(3):366-373. PubMed ID: 35366790
[TBL] [Abstract][Full Text] [Related]
36. The impact of COVID-19 pandemic on the number of first diagnosis and follow-up visits of patients affected by pemphigus, bullous pemphigoid, scleroderma, psoriasis and vitiligo: A single-centre experience.
Moro F; Mariotti F; Pira A; Sobrino L; Pallotta S; Panebianco A; Di Zenzo G
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e453-e455. PubMed ID: 38400642
[No Abstract] [Full Text] [Related]
37. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
38. Reply to 'development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2' by Solimani F et al.
Falcinelli F; Lamberti A; Cota C; Rubegni P; Cinotti E
J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e976-e978. PubMed ID: 35789506
[No Abstract] [Full Text] [Related]
39. Could mixing COVID vaccines boost immune response?
Ledford H
Nature; 2021 Feb; 590(7846):375-376. PubMed ID: 33547431
[No Abstract] [Full Text] [Related]
40. Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study).
Kiss Z; Wittmann I; Polivka L; Surján G; Surján O; Barcza Z; Molnár GA; Nagy D; Müller V; Bogos K; Nagy P; Kenessey I; Wéber A; Pálosi M; Szlávik J; Schaff Z; Szekanecz Z; Müller C; Kásler M; Vokó Z
Front Immunol; 2022; 13():905585. PubMed ID: 35812442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
